P16和Ki-67与宫颈癌患者HPV持续性感染的相关性研究
Relationship between Expression of P16 and Ki-67 and Persistent Infection of HPV in Cervical Carcinoma Patients
DOI: 10.12677/ACM.2018.88130, PDF,  被引量    科研立项经费支持
作者: 黄群欢, 金绍燕, 陆 欢:上海健康医学院附属第六人民医院南院,上海;洪 岭:同济大学附属第一妇婴保健院,上海
关键词: 宫颈上皮内瘤变免疫组织化学P16Ki-67人乳头瘤病毒Cervical Intraepithelial Neoplasia (CIN) Immunohistochemistry P16 Ki-67 Human Papillomavirus (HPV)
摘要: 目的:探讨P16和Ki-67表达与宫颈病变之间的关系,评估P16和Ki-67作为高危型人乳头瘤病毒(hr-HPV)持续感染预后标记物的意义。方法:纳入宫颈活检标本1369例,无癌前病变(NEG) 392例,宫颈上皮内瘤变I (CIN I) 519例,CIN II 257例,CIN III 154例,鳞状细胞癌(SCC) 47例。此外,306名CIN I患者被纳入为期12个月的随访中,使用HPV特异性引物通过聚合酶链反应方法检测宫颈分泌物中hr-HPV,随访期内每6个月检测一次。133名患者持续感染hr-HPV,94名一过性感染,79名未感染hr-HPV。免疫组织化学法检测P16和Ki-67的表达。P16和Ki-67的染色结果分为四类:阴性,1+,2+和3+。结果:与NEG相比CINs和SCC中P16和Ki-67的表达均显著增加(P < 0.01)。CIN III中P16和Ki-67的表达与CIN II相比均无显著性差异(P > 0.05)。P16阳性率与hr-HPV持续感染正相关(P < 0.05)。hr-HPV感染患者中P16以及Ki-67阳性率显著高于未感染hr-HPV的患者(P < 0.05)。结论:P16和Ki-67可提高宫颈病变的诊断准确性,P16表达与CIN I期患者hr-HPV持续感染存在相关性。
Abstract: Objective: To determine the association between the expression of P16 and Ki-67 and cervical le-sions, and to evaluate the role of P16 and Ki-67 as prognostic markers for persistent high risk human papillomavirus (hr-HPV) infection. Methods: Totally 1369 cases of cervical biopsies were enrolled, 392 cases with negative for dysplasia (NEG), 519 with cervical intraepithelial neoplasia I (CIN I), 257 with CIN II, 154 with CIN III and 47 with cervical squamous cell carcinoma (SCC). Fur-thermore, 306 women with CIN I were recruited into 12-month follow-up, and HPV specific gene detection by polymerase chain reaction was used to detect hr-HPV of cervical secretions at 6-month-interval for 12-month follow-up period. 133 women were infected with persistent hr-HPV, 94 with transient infection and 79 not infected with hr-HPV. The expression of P16 and Ki-67 was evaluated by immunohistochemical method. The immunostaining results of P16 and Ki-67 were classified into four categories: negative, 1+, 2+ and 3+. Results: There was significant increase in the expression of P16 and Ki-67 (P < 0.01) from NEG to SCC. There was no significant difference in the expression of P16 and Ki-67 between CIN II and CIN III (P > 0.05). Ratio of P16 positivity was positive correlated with persistent hr-HPV infection (P < 0.05). Ratios of P16 and Ki-67 in hr-HPV infection group were significantly higher than that of non-infection group (P < 0.05). Conclusion: P16 and Ki-67 can improve the diagnostic accuracy of cervical lesions. P16 expression is correlated with persistent hr-HPV infection in CIN I patients.
文章引用:黄群欢, 金绍燕, 陆欢, 洪岭. P16和Ki-67与宫颈癌患者HPV持续性感染的相关性研究[J]. 临床医学进展, 2018, 8(8): 776-783. https://doi.org/10.12677/ACM.2018.88130

参考文献

[1] Chih, H.J., Lee, A.H., Colville, L., et al. (2013) A Review of Dietary Prevention of Human Papillomavirus-Related in-fection of the Cervix and Cervical Intraepithelial Neoplasia. Nutrition and Cancer, 65, 317-328. [Google Scholar] [CrossRef] [PubMed]
[2] Rouzier, R. (2008) Management of CIN1. Journal de Gyné-cologie Obstétrique et Biologie de la Reproduction, 37, S114-S120. [Google Scholar] [CrossRef] [PubMed]
[3] Martin, C.M. and O’Leary, J.J. (2011) Histology of Cervical In-traepithelial Neoplasia and the Role of Biomarkers. Best Practice & Research Clinical Obstetrics & Gynaecology, 25, 605-615. [Google Scholar] [CrossRef] [PubMed]
[4] Munro, A., Leung, Y., Spilsbury, K., et al. (2015) Comparison of Cold Knife Cone Biopsy and Loop Electrosurgical Excision Procedure in the Management of Cervical Adenocarcinoma in Situ: What Is the Gold Standard? Gynecologic Oncology, 137, 258-263. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, E.Y., Tran, A., Raho, C.J., et al. (2010) Histological ‘Progression’ from Low (LSIL) to High (HSIL) Squamous Intraepithelial Lesion Is an Uncommon Event and an Indi-cation for Quality Assurance Review. Modern Pathology, 23, 1045-1051. [Google Scholar] [CrossRef] [PubMed]
[6] Creagh, T., Bridger, J.E., Kupek, E., et al. (1995) Pathologist Variation in Reporting Cervical Borderline Epithelial Abnormalities and Cervical Intraepithelial Neoplasia. Journal of Clinical Pathology, 48, 59-60. [Google Scholar] [CrossRef] [PubMed]
[7] Cheol Park, G., Roh, J.L., Cho, K.J., et al. (2017) 18F-FDG PET/CT vs. Human Papillomavirus, p16 and Epstein-Barr Virus Detection in Cervical Metastatic Lymph Nodes for Identifying Primary Tumors. International Journal of Cancer, 140, 1405-1412. [Google Scholar] [CrossRef] [PubMed]
[8] Woodman, C.B., Collins, S.I. and Young, L.S. (2007) The Natural History of Cervical HPV Infection: Unresolved Issues. Nature Reviews Cancer, 7, 11-22. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, Y.H., Chang, B., Choi, J.H., et al. (2016) Biochemical Fingerprints of Human Papillomavirus Infection and Cervical Dysplasia Using Cervical Fluids: Spectral Pattern Investigation. Mi-croscopy Research and Technique, 79, 966-972. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, L., Wang, P., Ren, Y., et al. (2016) Prevalence of High-Risk Human Papillomavirus (HR-HPV) Genotypes and Multiple Infections in Cervical Abnormalities from Northern Xinjiang, China. PLoS One, 11, e0160698. [Google Scholar] [CrossRef] [PubMed]
[11] Syrjanen, K. (2011) Persistent High-Risk Human Papilloma-virus (HPV) Infections as Surrogate Endpoints of Progressive Cervical Disease. Potential New Endpoint for Efficacy Studies with New-Generation (Non-HPV 16/18) Prophylactic HPV Vaccines. European Journal of Gynaecological Oncology, 32, 17-33.
[12] Kim, T.E., Kim, H.W. and Lee, K.E. (2014) Distribution of Human Papillomavirus 52 and 58 Genotypes, and Their Expression of p16 and p53 in Cervical Neoplasia. Korean Journal of Pathology, 48, 24-29. [Google Scholar] [CrossRef
[13] Wei, Q., Fu, B., Liu, J., et al. (2013) Combined Detection of p16 (INK4a) and IMP3 Increase the Concordance Rate between Cervical Cytologic and Histologic Diagnosis. International Journal of Clinical and Experimental Pathology, 6, 1549-1557.
[14] Xing, Y., Wang, C. and Wu, J. (2017) Expression of Geminin, p16, and Ki67 in Cervical Intraepithelial Neoplasm and Normal Tissues. Medicine (Baltimore), 96, e7302. [Google Scholar] [CrossRef
[15] Serour, Y., Bendahmane, M., Abbou Baker, F., et al. (2017) HPV Test by Hybrid Capture II for the Diagnosis of HR-HPV Persistent Infection. Médecine et Maladies Infectieuses, 47, 484-489. [Google Scholar] [CrossRef] [PubMed]
[16] Seraceni, S., De Seta, F., Colli, C., et al. (2014) High Preva-lence of HPV Multiple Genotypes in Women with Persistent Chlamydia Trachomatis Infection. Infect Agent Cancer, 9, 30. [Google Scholar] [CrossRef] [PubMed]
[17] Halec, G., Alemany, L., Lloveras, B., et al. (2014) Pathogenic Role of the Eight Probably/Possibly Carcinogenic HPV Types 26, 53, 66, 67, 68, 70, 73 and 82 in Cervical Cancer. The Journal of Pathology, 234, 441-451. [Google Scholar] [CrossRef] [PubMed]
[18] Das, C.R., Tiwari, D., Dongre, A., et al. (2018) Deregulated TNF-Alpha Levels along with HPV Genotype 16 Infection Are Associated with Pathogenesis of Cervical Neoplasia in Northeast Indian Patients. Viral Immunology, 31, 282-291. [Google Scholar] [CrossRef] [PubMed]
[19] Sari Aslani, F., Safaei, A., Pourjabali, M., et al. (2013) Evaluation of Ki67, p16 and CK17 Markers in Differentiating Cervical Intraepithelial Neoplasia and Benign Lesions. Iranian Journal of Medical Sciences, 38, 15-21.
[20] You, K., Guo, Y.L., Geng, L., et al. (2013) Correlation of Cervical Intraepithelial Neoplasia with Expressions of p16 and Ki67 in Exfoliated Cervical Cells in Fluid-Based Thin-Layer Samples. European Journal of Gynaecological Oncology, 34, 535-539.
[21] Volpi, C.C., Ciniselli, C.M., Gualeni, A.V., et al. (2018) In Situ Hybridization Detection Methods for HPV16 E6/E7 mRNA in Identifying Transcriptionally Active HPV Infection of Oropharyngeal Carcinoma: An Updating. Human Pathology, 74, 32-42. [Google Scholar] [CrossRef] [PubMed]
[22] Rabachini, T., Boccardo, E., Andrade, R., et al. (2018) HPV-16 E7 Expression Up-Regulates Phospholipase D Activity and Promotes Rapamycin Resistance in a pRB-Dependent Manner. BMC Cancer, 18, 485. [Google Scholar] [CrossRef] [PubMed]
[23] Guo, C.P., Liu, K.W., Luo, H.B., et al. (2011) Potent Anti-Tumor Effect Generated by a Novel Human Papillomavirus (HPV) Antagonist Peptide Reactivating the pRb/E2F Pathway. PLoS ONE, 6, e17734. [Google Scholar] [CrossRef] [PubMed]
[24] Dreyer, J.H., Hauck, F., Barros, M.H.M., et al. (2017) pRb and CyclinD1 Complement p16 as Immunohistochemical Surrogate Markers of HPV Infection in Head and Neck Cancer. Applied Immunohistochemistry & Molecular Morphology, 25, 366-373. [Google Scholar] [CrossRef
[25] Liu, Y., Alqatari, M., Sultan, K., et al. (2017) Using p16 Immunohistochemistry to Classify Morphologic Cervical Intraepithelial Neoplasia 2: Correlation of Ambiguous Staining Patterns with HPV Subtypes and Clinical Outcome. Human Pathology, 66, 144-151. [Google Scholar] [CrossRef] [PubMed]
[26] Golusinski, P., Pazdrowski, J., Szewczyk, M., et al. (2017) Is Immunohistochemical Evaluation of p16 in Oropharyngeal Cancer Enough to Predict the HPV Positivity? Reports of Practical Oncology and Radiotherapy, 22, 237-242. [Google Scholar] [CrossRef] [PubMed]